Detalles de la búsqueda
1.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Blood
; 143(7): 592-596, 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38048557
2.
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.
Lancet Oncol
; 24(10): 1119-1133, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37717583
3.
A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
Haematologica
; 2023 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37981892
4.
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
Hematol Oncol
; 40(5): 1009-1019, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35638723
5.
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma.
Am J Hematol
; 97(12): 1607-1615, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36198076
6.
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients.
Int J Mol Sci
; 23(20)2022 Oct 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36293315
7.
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Hematol Oncol
; 39(1): 41-50, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33085797
8.
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study.
Am J Hematol
; 98(9): E226-E229, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37340832
9.
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Ann Hematol
; 96(12): 2071-2078, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29063955
10.
A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role?
AJR Am J Roentgenol
; 209(1): 152-158, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28418695
11.
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Am J Hematol
; 90(7): 647-52, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25858483
12.
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
Ann Hematol
; 93(1): 123-8, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23864035
13.
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.
Expert Rev Anticancer Ther
; 24(6): 379-395, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38798125
14.
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight.
Leuk Res Rep
; 21: 100399, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38078287
15.
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features.
Nat Commun
; 15(1): 1551, 2024 Feb 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38378709
16.
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients.
Cells
; 13(8)2024 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38667272
17.
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.
Leukemia
; 38(3): 640-647, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38062124
18.
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma.
Haematologica
; 103(6): e277-e278, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29622654
19.
Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in in vitro and ex vivo models.
Haematologica
; 103(12): e602-e606, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30026343
20.
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.
Ann Hematol
; 92(9): 1271-80, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23660628